Patents by Inventor David A. Proia

David A. Proia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230190760
    Abstract: New treatments for Ikaros and/or Aiolos mediated disorders are provided that comprise administering an effective amount of a cereblon binder that degrades Ikaros or Aiolos by the ubiquitin proteasome pathway.
    Type: Application
    Filed: February 7, 2023
    Publication date: June 22, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: David Proia, James A. Henderson, Minsheng He, Andrew Charles Good, Andrew J. Phillips
  • Publication number: 20230046803
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: September 27, 2022
    Publication date: February 16, 2023
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Patent number: 11497733
    Abstract: A pharmaceutical composition comprising a PD-1 inhibitor and a Hsp90 inhibitor, or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole or 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate. Also provided is a method for treating cancer in a subject in need thereof, using the pharmaceutical composition described herein.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: November 15, 2022
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: David A. Proia, Patricia E. Rao
  • Patent number: 11491145
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: November 8, 2022
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Patent number: 11154538
    Abstract: This invention relates to methods of treating a patient with ovarian cancer having deficiencies in homologous recombination (HR) comprising administering to the patient (i) an effective amount of ganetespib, or a pharmaceutically acceptable salt thereof; and (ii) an effective amount of a DNA-damaging or repair-inhibiting agent.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 26, 2021
    Assignee: Synta Pharmaceuticals Corporation
    Inventor: David Proia
  • Publication number: 20200222374
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 16, 2020
    Inventors: Weiwen Ying, Dinesh U. Chimmanamada, David Proia
  • Patent number: 10500193
    Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: December 10, 2019
    Assignee: Synta Pharmaceuticals Corporation
    Inventor: David Proia
  • Publication number: 20190060285
    Abstract: This invention relates to methods of treating a patient with ovarian cancer having deficiencies in homologous recombination (HR) comprising administering to the patient (i) an effective amount of ganetespib, or a pharmaceutically acceptable salt thereof; and (ii) an effective amount of a DNA-damaging or repair-inhibiting agent.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 28, 2019
    Inventor: David Proia
  • Publication number: 20180221345
    Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: March 29, 2018
    Publication date: August 9, 2018
    Inventor: David PROIA
  • Publication number: 20180064689
    Abstract: A pharmaceutical composition comprising a PD-1 inhibitor and a Hsp90 inhibitor, or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the Hsp90 inhibitor is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole or 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate. Also provided is a method for treating cancer in a subject in need thereof, using the pharmaceutical composition described herein.
    Type: Application
    Filed: February 9, 2016
    Publication date: March 8, 2018
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David A. Proia, Patricia E. Rao
  • Publication number: 20170340652
    Abstract: A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
    Type: Application
    Filed: August 11, 2017
    Publication date: November 30, 2017
    Inventors: David Proia, Suqin He
  • Publication number: 20160324863
    Abstract: Methods of treating certain cancers with ganetespib or NVP-AUY922 are disclosed. Also provided are methods of treating cancer wherein the cancer has an FGFR3 mutation and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGT1A10. Also provided are methods of treating cancer with a mutation in FGFR3 and/or a low level expression of UGT1A, and/or a low level expression of UGT1A9 and/or UGTIA10, with ganetespib or NVP-AUY922, in combination with an FGFR3 inhibitor such as BGJ398 and AZD4547.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 10, 2016
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jaime Acquaviva, David Proia
  • Patent number: 9439899
    Abstract: A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 13, 2016
    Assignee: Synta Pharmaceuticals Corp.
    Inventor: David Proia
  • Patent number: 9402831
    Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 2, 2016
    Assignee: Synta Pharmaceutical Corp.
    Inventors: David Proia, Jaime Acquaviva
  • Publication number: 20160120849
    Abstract: A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
    Type: Application
    Filed: November 3, 2015
    Publication date: May 5, 2016
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • Patent number: 9205086
    Abstract: A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 8, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • Publication number: 20150283147
    Abstract: Provided are methods of treating polycystic kidney disease in a subject in need thereof, by administering to the subject in need thereof, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods of treating polycystic kidney disease by a compound of formula (I) in combination with additional therapeutic agents.
    Type: Application
    Filed: October 18, 2013
    Publication date: October 8, 2015
    Inventors: David Proia, Erica Golemis, Tamina Seeger-Nukpezah
  • Publication number: 20150150850
    Abstract: Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (Ia): a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein.
    Type: Application
    Filed: December 5, 2014
    Publication date: June 4, 2015
    Inventors: Iman El-Hariry, David Proia, Vojo Vukovic
  • Publication number: 20150099721
    Abstract: A method for treating cancer with a mutation in ROS or RET, comprising identifying a subject with a cancer with a mutation in ROS or RET, and administering to the subject an effective amount of a compound according to formulae (I) OR (la) or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 9, 2015
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jaime Acquaviva, Suqin He, David Proia
  • Patent number: 8906885
    Abstract: Methods of treating cancer with a compound of formulae (I) or (1a) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (1a). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (1a); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: December 9, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Iman El-Hariry, David Proia, Vojo Vukovic